A chromatin-associated and transcriptionally inactive p53-Mdm2 complex occurs in mdm2 SNP309 homozygous cells

Area of Science:

• Molecular Biology
• Cancer Biology
• Genetics

Background:

• The tumor suppressor protein p53 is crucial for preventing cancer but is often inactivated in tumor cells.
• A common polymorphism in the mdm2 gene (mdm2 SNP309) leads to Mdm2 overexpression, further impairing p53 function.
• Understanding how Mdm2 overexpression affects p53 activity is vital for cancer therapy.

Purpose of the Study:

• To investigate the mechanism by which Mdm2 overexpression, due to mdm2 SNP309, inhibits the tumor suppressor p53.
• To determine the impact of this inhibition on p53's transcriptional activity and target gene regulation.

Main Methods:

• Analysis of p53 and Mdm2 complex formation in mdm2 SNP309 cancer cells.
• Treatment with DNA-damaging agents (camptothecin, etoposide, mitomycin C) to induce p53.
• Chromatin immunoprecipitation (ChIP) to assess p53 and Mdm2 binding to DNA.
• Quantitative PCR to measure target gene transcription.
• RNA interference (siRNA) to inhibit Mdm2 expression.

Main Results:

• In mdm2 SNP309 cells, p53 forms a complex with Mdm2 without degradation, accumulating in the nucleus after treatment.
• Both p53 and Mdm2 bind to p53-responsive elements on chromatin.
• Despite DNA binding, p53 fails to activate transcription of its target genes in SNP309 cells.
• Exogenous p53 also fails to activate transcription, confirming an inhibitor effect.
• Mdm2 inhibition via siRNA restores transcriptional activation of p53 targets.

Conclusions:

• Overproduced Mdm2, driven by mdm2 SNP309, prevents chromatin-bound p53 from initiating target gene transcription.
• This mechanism highlights a critical pathway for cancer development and suggests potential therapeutic targets.